# Changing a Medical Device Representative in Southeast Asia (2026)

## TL;DR

Before appointing a distributor or a representative, identify whose name will appear on each local device registration, who will control the regulator account, and who can authorize the next shipment. Singapore and Malaysia publish cooperative procedures to change the holder of an existing registration. Thailand publishes a consent-based Full CSDT dossier transfer route for specified applications. In Indonesia, assess the transition under Permenkes No. 5 of 2026 and obtain confirmation of the cancellation, revocation or successor application path before scheduling a switch [1](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-1) [2](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-2) [3](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-3) [4](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-4).

Treat the registry figures as a map of links between names and registrations. The September Singapore extract shows that 3,405 of 3,823 product-owner names appear with one registrant. The June Thailand extract shows one Thai licence-holder name for 659 of the 771 foreign manufacturer names in the selected active import subset. In Malaysia, 1,877 of 2,103 licensed AR establishments also appear with importer or distributor licences. These are different populations. They help prioritize which records to reconcile for an individual manufacturer, and provide no direct measure of exclusivity, disputes or switching costs [5](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-5) [6](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-6) [7](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-7) [8](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-8).

A buying team should price representation, licence fees, importer charges, separate conformity assessment, and contract exit individually. Using Pure Global’s published starting annual rates for one registration per market, the hypothetical recurring representation line across four markets is $8,000 a year for the lower-risk example below or $11,000 for the higher-risk example, with a three-year base commitment. Confirm grouping, dossier work, pass-through fees and termination terms in an itemized proposal [Pure Global. Medical Device Consulting Pricing & Plans, Flat annual fee by market and pricing questions. Public starting one-listing rates, exclusions and contract terms.](https://www.pureglobal.com/services/pricing).

## 1\. Decide who can perform each local activity

Consider MedNova Diagnostics, a hypothetical foreign manufacturer entering Indonesia, Singapore, Malaysia and Thailand. It wants a monitoring system and a single-use probe kit sold under approved local product scopes. In the pricing example the kit is Class B or Class 2 and the monitor is Class C or Class 3 by assumption. Classification and grouping for actual products depend on national evaluation. The ASEAN documents support shared approaches to classification, dossier content and post-market coordination. Plan each national procedure separately [9](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-9) [10](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-10).

Its proposed Indonesian distributor offers to prepare and hold the first registrations in return for exclusivity. An alternative is a suitably qualified separately contracted holder. A subsidiary may also be eligible if the manufacturer can meet local qualifications, establish operations and staff ongoing responsibilities. Compare the time and obligations to change commercial partners in each model, and explicitly name who applies, holds the registration, may import, may distribute and acts on safety and regulatory items. The government may limit which actors can perform each activity. The manufacturer should retain access to relevant product and technical documentation, while separately agreeing what use each party can make of it [Pure Global, In-Country Representatives and Registration Holders, editorial guide.](https://www.pureglobal.com/blog-posts/in-country-representative-registration-holder-decision-2026) [11](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-11).

Choose a local appointment model that can support a handoverEvaluate who can perform the work and verify all required authorizations separately.Reference table
| Model to evaluate | Trade-off | Evidence before committing |
| --- | --- | --- |
| Distributor also holds registration | One commercial group may control several dependencies | Verify qualification, access to submissions and exit process |
| Separately contracted qualified holder | Clinical supply, registration and importer authority may have different owners | Confirm local eligibility, written permissions, continuity and fees |
| Qualified local subsidiary | Manufacturer controls the local organization and funds its obligations | Verify local licences, personnel, import and ongoing compliance coverage |

Source: Proposed model comparison; national procedures for Indonesia, Singapore, Malaysia and Thailand. https://farmalkes.kemkes.go.id/wp-content/uploads/2026/07/Permenkes-Nomor-5-Tahun-2026.pdf; https://isomer-user-content.by.gov.sg/409/73684ac1-e39c-42da-9a5d-46392462bcee/gn-24-r2-guidance-on-the-change-of-registrant-%282025-jul%29-pub.pdf; https://portal.mda.gov.my/index.php/documents/guidance-documents/816-41-change-ownership-for-md-registration/file; https://medical.fda.moph.go.th/product/category/transfer-detail-process/

For the distributor-holder, order and filing responsibility may sit in one organization where legal roles and licences cover the scope. Record its right to appoint or acknowledge an authorized successor and what is required when the commercial contract ends. For a separate services holder, verify that the government and contracts allow commercial partners to import and distribute under the proposed licences and appointment documents. For a subsidiary, price the people, licensed activities, warehousing or contract coverage and backup authority. Re-evaluate the model if product classification, distribution channels, ownership or applicable authorization changes. The matrix in Chart 05 gives the next question for each national actor, and the public counts in the following sections describe records rather than business performance.

For Singapore, the September analysis finds 3,405 of 3,823 normalized product owner strings linked to one registrant string, 317 to two and 101 to three or more. In Thailand, the June sample finds 659 of 771 foreign manufacturer names linked to one Thai holder name across selected active imports. The data supply early checks for how to search a product. They do not establish an exclusive contract or refusal to cooperate. In Malaysia the two source snapshots can match an authorization holder to multiple statutory licence roles. No record-level match establishes legal ownership or how a company uses those roles [5](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-5) [6](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-6) [7](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-7) [8](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-8).

## 2\. Indonesia: verify the applicable transition and change path

Indonesia's Ministry of Health adopted Permenkes No. 5 of 2026 under the wider health law framework. It addresses regulation of health supplies and repealed prior instruments including No. 62 of 2017. Read the current text, the applicable transitional and saved-instrument provisions, and the status and terms of the specific registration. Check the relevant licensing rules for the distributor, importer and product. Confirm which instructions and systems the authority uses for the planned transaction; confirm effective authorization independently from any portal field [1](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-1) [12](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-12) [13](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-13) [14](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-14).

In Pure Global's November 19 InfoAlkes product snapshot, 64,210 of 84,177 unique selected active entries were imported AKL registrations (76.3%), while 19,967 were domestic AKD. Chart 02 shows counts for visible risk categories. It excludes one AKL record and one AKD record from the full snapshot totals because they sit outside the charted classifications. These counts measure registered items, not import shipments or local supplier capacity [15](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-15).

Indonesia Active Medical Device Registrations by Risk Class: Imported (AKL) vs. Domestic (AKD), November 2026The chart shows four recorded risk classes. The full snapshot has one AKL and one AKD records outside the displayed groups.Records
|  | Imported (AKL) | Domestic (AKD) |
| --- | --- | --- |
| Class A | 17,602 | 8,344 |
| Class B | 28,751 | 9,224 |
| Class C | 15,262 | 2,153 |
| Class D | 2,594 | 245 |

Source: Indonesia Ministry of Health product search; November 19, 2026 Pure Global snapshot. https://mobilealkes.kemkes.go.id/cari-produk

A separate July snapshot has 7,211 IDAK licence records, including 4,469 (62.0%) recorded in DKI Jakarta, Jawa Barat and Banten provinces. The compared extracts found 1,791 exact normalized holder-name matches among 2,732 AKL holder-name strings. Treat other names as unresolved, and verify by licence number, legal name and the actual registration. Ask whether a candidate can cover the required ports, languages, compliance tasks and regional distribution. A licence count supplies no test of an establishment's staff, market reach or other OEM obligations. Review competition, service coverage and access during diligence using separate evidence [15](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-15) [16](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-16).

### Reading legacy Indonesian certificates during the transition

The two historical licensing considerations are the local appointment and its connection with the product dossier. The former Permenkes No. 62 of 2017 addressed both. It has been repealed, so its term and sole-agent provisions cannot be applied to every filing today by citation alone [13](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-13). Under the 2026 regulation, Article 122 provides up to one year from promulgation for alignment of the rules on the administration of health supplies. Article 124 preserves implementing provisions to the extent compatible with the new regulation, and Article 125 lists the repealed rules [1](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-1). The e-Regalkes technical guide historically identifies change of distributor as a situation requiring a new application. For each existing licence, ask the authority which instructions are operative for that product and whether the old authorization can support proposed shipments before cutover [17](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-17).

The working extract contains 64,210 active AKL rows. The figure classifies the difference between the printed issue year and expiry year, excluding 20 records with out-of-scope or anomalous date fields. The eligible denominator is 64,190. Of these, 20,008 show five calendar years between the two dates, and 44,182 show zero to four calendar years [15](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-15). The workflow implication is narrow. Build a renewal calendar from the exact certificate dates and independently verify the timing and status of each appointment. The year difference reveals neither the original term nor why an authority chose the expiry date.

Calendar-year differences between issue and expiry on Indonesian AKL records20,008 of 64,190 eligible records have a five-year difference between the printed years. Another 44,182 have differences of zero to four years. The comparison uses years, not elapsed months, and excludes 20 anomalous records.Records
|  | Active AKL Registrations |
| --- | --- |
| 0–1 calendar-year difference | 2,111 |
| 2 calendar-year difference | 6,726 |
| 3 calendar-year difference | 16,843 |
| 4 calendar-year difference | 18,502 |
| 5 calendar-year difference | 20,008 |

Source: Indonesia Ministry of Health product search; November 19, 2026 Pure Global snapshot and issue/expiry-year difference. https://mobilealkes.kemkes.go.id/cari-produk

### When the current Indonesian holder refuses to cooperate

Keep three branches open until the applicable path is confirmed. In a cooperative exit, agree what the current holder will submit and how the replacement party will establish its appointment, file the verified dossier and receive authority instructions. Record the date at which each party can take the next permitted action and the effective date on the regulator’s decision [1](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-1) [17](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-17).

For a disputed exit, Article 51(1)(d) permits revocation after the manufacturer terminates the distributor or importer appointment. Confirm the evidence and procedure with the authority and local counsel. Revocation and replacement authorization are separate acts. Before issuing notice, have the regulatory lead document the effect on certificates, current stock, customs entries and post-market coverage. The manufacturer should confirm the official route where a cooperative release is unavailable and whether the successor can start any filing steps before a prior registration ends [1](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-1) [17](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-17) [16](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-16).

Treat a successor application as its own workstream. Identify the local eligible applicant, check OSS and e-Regalkes information against the product record, secure the relevant appointment documentation and line up application and evaluation costs. Obtain the government fee applicable on the filing date [18](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-18). The compliance lead should release a shipment or a new label only when the required authorization, valid importer information and permitted effective date are all evidenced. Keep the complaint line and authorities’ safety obligations covered during any commercial dispute [1](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-1) [10](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-10) [14](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-14).

* * *

## 3\. Verify the actor map in Singapore, Malaysia and Thailand

Four-country actor and approval mapThe legal authority, accountable entity and permission for the next shipment depend on the country and device.Reference table
| Market | Product roles and authority | Import, distribution and next action |
| --- | --- | --- |
| Indonesia | Document eligible local applicant, current holder and Ministry route | Verify each licensed activity and exact permit and successor path |
| Singapore | Product owner appoints applicant; registrant holds listing; HSA processes change | HSA dealer licence for applicable activity and written importer authorization from registrant where required |
| Malaysia | Foreign manufacturer appoints AR; incoming AR applies to MDA under applicable route | Verify establishment licence for each applicable activity and needed GDPMD; transfer records by approval date |
| Thailand | Confirm local establishment and product holder; Thai FDA evaluates qualifying Full CSDT application | Verify authority for import or distribution; template cancellation on approval and outgoing closure documents within 30 calendar days |

Source: National procedures and licence roles for Indonesia, Singapore, Malaysia and Thailand. https://farmalkes.kemkes.go.id/wp-content/uploads/2026/07/Permenkes-Nomor-5-Tahun-2026.pdf; https://isomer-user-content.by.gov.sg/409/73684ac1-e39c-42da-9a5d-46392462bcee/gn-24-r2-guidance-on-the-change-of-registrant-%282025-jul%29-pub.pdf; https://sso.agc.gov.sg/SL/HPA2007-S436-2010; https://portal.mda.gov.my/index.php/documents/guidance-documents/816-41-change-ownership-for-md-registration/file; https://portal.mda.gov.my/index.php/documents/regulation/685-medical-device-act-2012-eng/file; https://medical.fda.moph.go.th/product/category/transfer-detail-process/

### Singapore: registrant change, dealer licences and maintenance

In Singapore, identify the product owner, the local registrant or applicant, the applicable dealer licensees and which authority issues or approves each record. Verify the product route under the Health Products Act and Medical Devices Regulations. HSA grants relevant importer and wholesaler licences; written authorization for import of a registered device is issued by the registrant. The product owner normally authorizes the local company under the applicable registration route. Commercial partners may hold dealer licences for their actual activities, and the current regulations and conditions determine the route for the particular device. The Class A system and Class B–D registration serve different device categories [19](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-19) [20](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-20) [21](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-21) [22](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-22).

For a cooperative change under GN-24 Revision 2, the accepting company applies through SHARE for a device already on the Singapore Medical Device Register. Use one application per product owner. Related pending applications for the listed device, such as a change notification or cancellation, must be completed or withdrawn before filing. Keep at least two months of listing validity before retention is due. Prepare the product owner's letters of appointment and request and the outgoing company's signed relinquishing declaration. The current HSA schedule lists SGD 880 and a target of 40 working days. HSA measures the target from receipt and excludes time stopped for clarification and additional information. Plan supply against the current verified permissions and the actual decision date [2](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-2) [20](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-20) [21](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-21) [22](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-22).

For the GN-24 Annex 1 request, HSA directs the product owner to enter an appointment date before application submission. The regulatory change takes effect on HSA approval. HSA updates the listing to reflect the incoming company, and outgoing access to that listing ends immediately. GN-24 says the accepting company has access to the prior submitted information and dossiers through the regulatory system. Supply and complaint records follow a separate decision. GN-24 allows the outgoing company to retain them for the applicable period or transfer them. If it retains them, it must provide the records to the accepting company or HSA when required in the circumstances described in Section 3. The accepting company's obligations begin at the effective change and it pays retention fees at the next exercise. Record contact and access commitments before relying on a new partner to respond to an incident [2](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-2) [19](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-19) [20](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-20).

The September snapshot has a recorded Change Notification approval date on 12,629 of 20,858 listings (60.55%). The date field alone supplies no count of changes, work or fees. Use HSA GN-21 to assess the actual proposed change. Depending on category and context, it may need no notification, acknowledgement, prior approval or another filing route. Include an approval owner and documented rationale and preserve records for any required submission in the migration plan. Pure Global's separate article discusses post-approval change operations as editorial analysis [7](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-7) [21](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-21) [23](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-23) [Pure Global, APAC and LATAM Post-Approval Device Change Control, editorial workpaper.](https://www.pureglobal.com/blog-posts/apac-latam-post-approval-device-change-control-singapore-malaysia-hongkong-mexico-2026).

### Malaysia: change of ownership and continuity of the required duties

For a foreign manufacturer, identify the authorized representative (AR) who can apply and hold a relevant registration, the importer and distributor licensed for the corresponding activities, and the responsible authority. Ask the organization to show its current establishment licence covering each activity, applicable GDPMD evidence and effective dates. Use the MeDC@St channel and applicable documents for submissions and check the precise requirements with MDA. Roles can sit within one qualified organization or separate ones where the actual arrangements allow [11](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-11) [24](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-24) [25](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-25) [26](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-26).

In the March establishment extract, 2,103 names have an AR role. Of these, 1,877 also have an importer or distributor licence role (89.3%, rounded), and 208 match an AR-only category. The remaining 18 names are outside those groups. In the November product snapshot, 40,455 of 49,796 records match AR names also licensed to import or distribute, and 4,644 match AR-only names. Chart 04 uses the supplied device-record grouping and displays unmatched names separately. A name with no match could have name, timing or coverage differences, so retain it as unresolved. The grouped figures do not resolve which entity owns another or performs a role for each listing. The two explicitly identified matched AR groups contain 45,099 records. The other matched group has not been independently resolved into narrower AR subclasses in this workpaper [5](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-5) [6](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-6).

Malaysia MDAR records by matched establishment-licence roleDevice records matched by normalized establishment name, including 1,140 unmatched records. The aggregates cannot establish commercial structure.Records
|  | Active MDAR Registrations |
| --- | --- |
| Matched AR with importer or distributor licence role | 40,455 |
| Matched AR-only licence role | 4,644 |
| Other matched roles or establishments | 3,557 |
| Unmatched establishment strings | 1,140 |

Source: Malaysia MDA device and licensed-establishment searches; Pure Global November 19 and March 10, 2026 snapshots respectively. https://mdar.mda.gov.my/frontend/web/?r=carian; https://mdar.mda.gov.my/frontend/web/?r=carianfrontend/web?r=carian-el%2Findex

For the formal change of ownership, review MDA/GD/0041 conditions, active record status, pending lifecycle work and Annex B and surrender or other custody evidence. The incoming AR obtains the manufacturer appointment and files in the applicable system. The guidance describes a MYR 500 processing fee and retention of the registration’s remaining validity for the approved change. Verify the current conditions and treatment of conformity assessment for the specific device before pricing. If a required declaration is unavailable, ask MDA which authority procedure is appropriate before assuming a fresh application can start or supply continue. For new Class A filings and re-registration in scope from January 1, 2026, the amended fee entries are MYR 500 at application and MYR 750 at registration. Confirm fees for the actual device and route [3](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-3) [11](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-11) [25](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-25) [27](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-27).

The incoming AR takes possession of relevant records through the approval date under the guidance. Map complaints, corrections, distribution and other records, and preserve access to information about earlier supply. Identify the responsible roles after approval and participation by the manufacturer and prior suppliers for unresolved issues. Apply required reporting and corrective action under the relevant legislation and duties. An agreement on party cooperation and costs does not determine statutory obligations [3](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-3) [11](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-11) [24](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-24) [28](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-28).

### Thailand: identify the document that the Full CSDT route can transfer

Thai FDA’s Medical Device Control Division administers relevant establishment and product authorizations. Map legal manufacturer, local applicant and establishment registration holder, holder of the product licence or detailed notification, and the permitted importer and distributor roles to the device and proposed route. Thai FDA’s transfer procedure covers Full CSDT applications for the specified licence and detailed-notification types. For a template registration in Partial format, Thai FDA requires the template holder to supplement the dossier to Full CSDT before transfer [4](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-4). Confirm product type and establishment status first. Include the updated declaration of conformity and, for an import application, the product owner authorization as applicable. The file also includes the prescribed identicality, consent and safety declaration documents [4](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-4) [29](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-29) [30](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-30).

On approval of the transferred dossier application, the template registration is cancelled under the published procedure. The template holder then has 30 calendar days to submit the closure documents. Verify which authorization is effective, how the cancellation is recorded, which shipments the incoming holder can support and who owns safety and record custody. The Thai FDA establishment FAQ refers to renewal from October 1 through December 31 in the expiry year for establishment registrations, with a qualified late January allowance and daily penalty in that FAQ. Obtain the product-specific instructions instead of applying the establishment rule to the certificate [4](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-4) [31](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-31).

The sampled June catalogue has 99,734 unique records, including 26,680 marked active, 71,328 expired, 885 cancelled and 827 unable to produce or import. Fourteen records remain outside the stated categories and unresolved. Treat the 13,861 selected active import records and the derived names under Section 1 as describing that sample, not the entire Thai market. Verify the applicant, exact product and distributor rights from the actual documents needed for the transaction [8](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-8).

## 4\. Verify the handover before signing the appointment

### Confirm who can act and which records they hold

Use a product-by-market register. For each row record the holder shown by the regulator, legal and local applicant and each party permitted to import, wholesale or distribute. Capture licence scope, issuer, effective date, product classification, dossier revision and approved label, renewal, open changes and assigned post-market contacts. Record the evidence distinct from a trade or marketing statement. Verify what evidence the incoming and outgoing parties can retain and exchange, and who has responsibility and access during the transition. Review applicable local law and authority instructions alongside any proposed obligations from this section [1](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-1) [2](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-2) [3](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-3) [4](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-4).

For Indonesia, reconcile the identifiable applicant, current appointment, authorization and activity documentation. For Singapore, the product owner mandate and the registrant's importer authorization answer distinct questions. For Malaysia, evaluate the AR and activity-specific licence records and check what the current workflow requires. For Thailand, check the applicable establishment record and product-level route separately from the sale or distribution agreement. For every market, obtain a controlled record for each expiry and renewal date and ask who is able to submit an appropriate renewal if the representative is being replaced. Do not infer scope from a general statement by a provider [1](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-1) [4](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-4) [20](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-20) [11](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-11) [26](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-26) [31](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-31).

### Propose contract clauses for the actual exit risk

1.  **Appointment and review date.** Use a contract review period proportionate to the relationship and confirm that it is compatible with the actual authorization, issuer’s rules and renewal steps. A review date can give the manufacturer time to consider alternatives. A regulator filing or authorization may be required separately [1](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-1) [13](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-13).
2.  **Cooperation and evidence.** Agree time to respond, applicable handover documents, how to record refusal or unresolved items, and the person who can act as backup. Obtain advice on the enforceability and effect of any consent covenant, escrow or invoice retention. In a cooperative case, prepare the appropriate instruments for the proven procedure. Confirm approval, cancellation and closure separately. In a dispute, any enforcement or remedy remains subject to the applicable law and facts [1](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-1) [2](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-2) [3](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-3) [4](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-4).
3.  **Dossier access and rights.** Identify what translations, records, screenshots, written authorization and accepted dossier can be shared or retained under applicable rights and privacy. Specify version, update interval, recipient and emergency access. A contractual obligation to deliver a copy is not ownership of the government account or licence.
4.  **Licensed distribution.** Where the arrangement permits licensed commercial partners, define the authorized signatory and how written permissions and record updates apply. Price processing and handoff where relevant. Check the regulator’s decision independently of any private appointment. The entity must hold the licence required for the activity [20](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-20) [11](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-11).
5.  **Renewals and open changes.** Agree early notice, proof of current retention or applicable renewals, and a process for necessary open changes, separating product, establishment and agency timelines. In Malaysia, check the change-of-ownership implications of open items. Preserve the ability to address legally required, urgent or safety actions while a voluntary migration freeze is planned [2](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-2) [3](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-3) [22](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-22) [23](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-23) [31](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-31).
6.  **Complaints and field action.** Prepare evidence of process coverage through the actual date. Agree how each party escalates complaints about pre-transfer lots, where the relevant records are stored and who can retrieve them if commercial authority is withdrawn. Match each participant's applicable obligations and make sure required reporting and field action can continue on their own clocks [3](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-3) [10](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-10) [24](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-24).

### Record which permissions allow the next shipment

Build the transition record from planned dispatch and arrival dates. A commercial appointment, HSA product record and importer authorization can have different effective dates. Document which party can hold or release each shipment and which party maintains complaints, vigilance and the sold-lot history. The local broker uses the applicable import records at dispatch and entry; the manufacturer owns the decision to hold stock before dispatch and the handling of affected orders [1](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-1) [2](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-2) [3](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-3) [4](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-4) [10](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-10) [20](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-20).

### Work through a delayed Singapore cutover

Assume MedNova makes the NovaSense Probe Kit and has two shipments of the currently registered kit scheduled to two Singapore hospitals. There are 300 sellable kits already held by the outgoing distributor for verified local supply, and each hospital expects a further 200. The existing registrant is cooperating and the incoming registrant has a signed product-owner authorization. The incoming importer holds its own importer licence. Under the applicable device registration and route, the registrant's written authorization for import is also needed. Put the two documents in different fields. The accepting company filed a complete application earlier after checking the registration and confirming there were no conflicting applications. MedNova plans to switch operations on September 10 in this hypothetical exercise. The planned dates, counts and commercial terms are assumptions and do not model an HSA service deadline [2](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-2) [20](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-20) [21](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-21).

On September 8, the regulatory lead checks the HSA status. The transfer is still being reviewed. The SMDR listing remains valid throughout the example and meets the filing retention condition. The existing registrant’s written authorization to the outgoing importer expires on September 12 under the hypothetical terms. Both the current authorized local supply arrangement and the approved device labelling cover the stock already in Singapore. The outgoing distributor has agreed to serve Hospital A and documents the 200 kits it will supply from local stock. The regulatory and quality leads confirm the distributor, lot, label and complaint contact for that sale, and the local inventory owner releases those 200 under documented existing permissions. The remaining 100 are available only within the verified route and scope. The transfer application has no bearing on those older records without a change in the legal conditions [2](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-2) [19](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-19) [20](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-20).

Hospital B's 200 kits are still outside Singapore. Its planned receipt is after September 12, and MedNova has no written authorization that covers the intended licensed importer on September 13 while the transfer is still pending. The regulatory operations lead marks that shipment held at origin. The incoming importer’s own licence and the product owner’s appointment letter give distinct evidence. The registrant’s written import authorization is still missing. The broker places a matching hold on the entry pack and records its exact release condition. An early shipment under the old path is an option if the compliance lead can confirm the required documents and permissions for the actual import timing. A commercial invoice prepared earlier gives no basis to proceed under the new route [2](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-2) [20](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-20).

Assume that on September 16 HSA confirms the holder change and its effective date for the existing registered model. The incoming registrant gives written authorization to the licensed importer on September 17. The regulatory lead verifies the authorization scope and labelled device against the specific shipment. The broker confirms its entry record, and the quality lead verifies that the label used is permitted for that configuration and lot. The authorized supply owner releases Hospital B's 200 kits on September 18. The reason is the completed set of device-level and importer records, documented within their effective period. Keep the prior hold, events and reviewed versions in the order history and notify the two hospitals of the applicable stock and complaint contacts [2](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-2) [19](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-19) [20](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-20).

The facts that would reverse the outcome belong in the same register. If the Sept. 16 decision covered a different model, the missing condition would still hold the second shipment. If a proposed labeling change or kit revision required another action under the authority's applicable change categories, MedNova would use the verified configuration or wait for that separate decision. Rehearse a complaint about Hospital A's older lot after Hospital B's release. The current responder needs the source of the sold-lot evidence, the person who can assess the issue and the record of any applicable reporting action. The outgoing partner may still hold relevant evidence even where the incoming party now owns a duty. Allow access and preserve the commitments in the handoff through the dates agreed with the involved parties [2](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-2) [20](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-20) [23](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-23).

For the purchase comparison, suppose the held 200 kits would cover a 20-kit daily requirement for ten days, the remaining 100 local kits could cover only five days if legally available to that buyer, and the hospital could verify an existing authorized backup for two days. A delay beyond seven days would still require a confirmed alternate plan. In the stated branch the parties can check whether the customer can actually accept partial supply from the older lot, how its demand has changed and what waiting will cost. Keep the sales-delay calculation distinct from the documented shipment release and clinical suitability of any backup. Build contingency stock before the cutover when a qualified partner and authorized sale allow it.

## 5\. Compare representation, authority and import costs

Use the public starting single-listing rates as inputs to a like-for-like budget. The written offer should confirm risk band, local grouping, the work needed from the dossier owner and the exact product and services covered. Build separate lines for annual representation, authority fees, conformity assessment, dossier gaps and physical importation. Check whether the offer permits a reviewed transfer and what exit and handoff work is covered [Pure Global. Medical Device Consulting Pricing & Plans, Flat annual fee by market and pricing questions. Public starting one-listing rates, exclusions and contract terms.](https://www.pureglobal.com/services/pricing).

| Market | Government fees to verify | Starting annual fee per listing | Risk-band scope in the published rates |
| --- | --- | --- | --- |
| Indonesia | Check the applicable PNBP fee basis for the filing [18](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-18) | USD 2,000 | All classes |
| Singapore | Check the HSA application and applicable evaluation or change-of-registrant fee [22](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-22) | USD 2,000 or USD 3,000 | Low/medium or medium/high |
| Malaysia | Check application, registration or ownership change and any separate CAB scope [27](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-27) | USD 2,000 or USD 3,000 | Low/medium or medium/high |
| Thailand | Check the applicable product route and establishment charges [30](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-30) | USD 2,000 or USD 3,000 | Low/medium or medium/high |

The provider describes ordinary representation, dossier compilation and submission for these markets, covered post-approval work and local-language translation from English for required regulatory documents. It excludes translations into English, marketing translations and certified translations. Price government fees, third-party fees and import handling separately. The published Indonesia and Thailand import fee is 2% of import value, with a USD 300 minimum and a USD 1,000 maximum per importation. The three-year contract terms describe a 50% payoff on the remaining value for early termination and a 50% higher first-year fee for a one-year contract. Confirm that the actual offer and authorized arrangement match these assumptions [Pure Global. Medical Device Consulting Pricing & Plans, Flat annual fee by market and pricing questions. Public starting one-listing rates, exclusions and contract terms.](https://www.pureglobal.com/services/pricing).

Three-year starting representation budget for one listing per marketThe budget uses the public starting annual rates for one listing in each of four markets over three years. Separate authority, import handling and third-party charges.Reference table
| Market | Lower example (USD) | Higher example (USD) |
| --- | --- | --- |
| Indonesia | 6,000 | 6,000 |
| Singapore | 6,000 | 9,000 |
| Malaysia | 6,000 | 9,000 |
| Thailand | 6,000 | 9,000 |
| Four-market total | 24,000 | 33,000 |

Source: Pure Global Medical Device Consulting Pricing & Plans. https://www.pureglobal.com/services/pricing. Hypothetical starting values.

### Worked Multi-Market Example: MedNova's Four-Market SEA Rollout Budget

For MedNova, compare one local registration in each of the four markets in both examples. Assume the appropriate quote matches the published starting rate for each assigned band. Calculate the recurring provider component for a three-year term.

-   **Scenario 1 — Single Class B / Class 2 Consumable (_NovaSense Probe Kit_, one local registration in each of four markets):** Indonesia (\*\*$2,000/yr **) + Singapore (**$2,000/yr **) + Malaysia (**$2,000/yr **) + Thailand (**$2,000/yr **) = **$8,000/yr flat \*\* (**$24,000 over three years**), plus applicable government and third-party fees [Pure Global. Medical Device Consulting Pricing & Plans, Flat annual fee by market and pricing questions. Public starting one-listing rates, exclusions and contract terms.](https://www.pureglobal.com/services/pricing).
-   **Scenario 2 — Single Class C / Class 3 Capital System (_NovaPulse Monitor M4_, one local registration in each of four markets):** Indonesia (\*\*$2,000/yr **, flat across all classes) + Singapore (**$3,000/yr **) + Malaysia (**$3,000/yr **) + Thailand (**$3,000/yr **) = **$11,000/yr flat \*\* (**$33,000 over three years**), plus applicable government and third-party fees [Pure Global. Medical Device Consulting Pricing & Plans, Flat annual fee by market and pricing questions. Public starting one-listing rates, exclusions and contract terms.](https://www.pureglobal.com/services/pricing).

For a pricing sensitivity, suppose the lower-band four-market quote equals the USD 8,000 annual starting total. If the company leaves a three-year agreement after exactly one completed year and all markets terminate together, the remaining two years are USD 16,000 and the stated 50% termination payoff is USD 8,000. The total through that decision would be USD 16,000 before fees and exit work. A one-year offer at the stated 50% increase would be USD 12,000 before fees. Under those assumptions, after one year the shorter term is USD 4,000 cheaper, while keeping the three-year term to completion uses the published starting USD 24,000. These calculations assume the price and termination treatment apply uniformly and that any notice and renewal requirements are met. Compare the signed options over a common period. A rolling one-year renewal cost needs a separate offer [Pure Global. Medical Device Consulting Pricing & Plans, Flat annual fee by market and pricing questions. Public starting one-listing rates, exclusions and contract terms.](https://www.pureglobal.com/services/pricing).

Quote import handling against shipment value and frequency when evaluating the bridge. At the provider's stated Indonesia and Thailand terms, 2% of a USD 10,000 shipment is USD 200, which is below the USD 300 minimum. Two distinct USD 10,000 shipments would therefore be USD 600 in provider handling, while one USD 20,000 shipment at the same rate would be USD 400. At USD 60,000 the percentage is USD 1,200, above the USD 1,000 maximum. Consolidation can change fees and change exposure to a delayed approval or an interrupted shipment. Compare planned warehouse stock, the time needed to ship replacements and actual eligibility dates for each movement. The quoted handling charge leaves government fees, duties, freight, tax and other costs to their own lines [Pure Global. Medical Device Consulting Pricing & Plans, Flat annual fee by market and pricing questions. Public starting one-listing rates, exclusions and contract terms.](https://www.pureglobal.com/services/pricing).

For the hypothetical $400,000 annual territory, a six-month interruption might shift $200,000 in expected sales into later periods, assuming a uniform sales rate. If half later ships and half is permanently lost, at a 30% contribution margin the direct lost contribution is $30,000, before incremental freight, refiling, bridge stock or dispute costs. If all sales are recovered, estimate only timing and incremental costs. Compare the resulting expected range against the proposed fees, the probability each model can avoid an interruption, and the fees for leaving a provider. A lower margin, shorter gap or lower dispute probability can change the decision.

Put the term and interruption analyses on the same decision horizon. Consider the lower-rate examples if the buyer expects to exit both alternatives after a year. Assume independently validated contingency arrangements reduce the hypothetical probability of the USD 30,000 lost contribution event from 20% to 5%. The modeled reduction in expected loss is USD 4,500, before contingency cost. If the only change is earlier exit under the one-year option, its USD 4,000 contract difference still applies under the example's assumptions, while the USD 4,500 benefit belongs with the actual continuity arrangements. If those arrangements cost USD 5,000, the modeled expected interruption savings alone fall USD 500 short. At USD 3,000, expected net savings under the same assumptions are USD 1,500. A smaller risk difference, a higher fee, or a different exit date can change the choice. Use documented stock and permissions to decide which continuity option is feasible. Price the option independently of the assumed advantage and consider the full potential loss as well as its expected value.

Choose the structure against the work the company can actually staff. A qualified distributor-holder can suit a market with one channel and an affordable exit plan. A separately contracted registrant can reduce exposure to a distributor change if local rules let licensed partners import and distribute under the agreed arrangement. A qualified subsidiary gives the manufacturer more direct operational control and carries its own staffing, permissions, audit and operating costs. For every model, check representation termination, fee obligations, import continuity and the cooperation the authorities may still require.

* * *

## 6\. Scope of the register and tariff inputs

Product extracts and licence extracts describe records. Indonesia's November 19 extract has 84,177 active records after assigning one row per registration number, 64,210 AKL and 19,967 AKD. Of the 64,210 AKL, 20 are excluded from the printed-year comparison, leaving 64,190. The July Indonesian IDAK extract describes licence records independently. Match exact normalized names for the stated query, preserving unresolved cases. A field related to a manufacturer or distributor can have varying access across the public automated and individual product views [15](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-15) [16](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-16).

Singapore's September 3 extraction groups named product owners and registrants by normalized strings and deduplicates product registration numbers. The MDAR and Malaysian licence figures use the November 19 and March 10 snapshots respectively, with suffix and punctuation normalization and splitting of multi-role strings. The unmatched MDAR group includes 1,140 device records across 264 strings; identify the exact account or authorization directly when consequential. Thailand's June 22 term-expanded public sample works at the stated product ID and name level. The manufacturer name counts leave corporate connections unresolved. Use the regulator records for the actual device and actor [5](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-5) [6](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-6) [7](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-7) [8](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-8).

Manufacturer roles and filing steps are based on the specific authority documents cited at their point of use. For Indonesia review the applicable transition and dated fee text. In Singapore and Malaysia verify the current fee and forms against the actual filed service. Thailand's authority materials and the provider's published price page describe distinct charges. Obtain official fee confirmation and a written provider scope at the quote date, and document the basis for any classified higher cost [1](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-1) [2](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-2) [3](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-3) [4](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-4) [Pure Global. Medical Device Consulting Pricing & Plans, Flat annual fee by market and pricing questions. Public starting one-listing rates, exclusions and contract terms.](https://www.pureglobal.com/services/pricing) [18](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-18) [22](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-22) [27](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-27) [30](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#ref-30).

## 7\. Approve the cutover when each dependency has evidence

Sign the commercial, regulatory and traceability decisions with the same product identifiers and their applicable evidence. The appointment owners should be able to show a reviewer why the next shipment can move or what is still holding it.

The retained price example shows recurring provider fees for defined hypothetical classes and grouped products, with other expenses to be priced. Use the exit cost, contractual term and available models to decide which organization should hold the required approvals. Pure Global's market-specific service scope is available in its published materials and should be confirmed for the actual application or transfer [Pure Global. Medical Device Consulting Pricing & Plans, Flat annual fee by market and pricing questions. Public starting one-listing rates, exclusions and contract terms.](https://www.pureglobal.com/services/pricing) [Pure Global, In-Country Representatives and Registration Holders, editorial guide.](https://www.pureglobal.com/blog-posts/in-country-representative-registration-holder-decision-2026).

## References

1.  [Indonesia Ministry of Health. Permenkes No. 5 Tahun 2026, Articles 50, 51 and 122–126.](https://farmalkes.kemkes.go.id/wp-content/uploads/2026/07/Permenkes-Nomor-5-Tahun-2026.pdf) farmalkes.kemkes.go.id [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-1-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-1-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-1-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-1-4) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-1-5) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-1-6) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-1-7) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-1-8) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-1-9) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-1-10) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-1-11) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-1-12)
2.  [Singapore HSA. GN-24: Guidance on the Change of Registrant, Revision 2, July 2025, Sections 2–4 and Annexes 1–2.](https://isomer-user-content.by.gov.sg/409/73684ac1-e39c-42da-9a5d-46392462bcee/gn-24-r2-guidance-on-the-change-of-registrant-%282025-jul%29-pub.pdf) isomer-user-content.by.gov.sg [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-2-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-2-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-2-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-2-4) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-2-5) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-2-6) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-2-7) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-2-8) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-2-9) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-2-10) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-2-11) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-2-12) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-2-13)
3.  [Medical Device Authority Malaysia. MDA/GD/0041, Change of Ownership for Medical Device Registration, sections 4–6 and Annexes A and B.](https://portal.mda.gov.my/index.php/documents/guidance-documents/816-41-change-ownership-for-md-registration/file) portal.mda.gov.my [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-3-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-3-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-3-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-3-4) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-3-5) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-3-6) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-3-7) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-3-8) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-3-9)
4.  [Thai FDA, Medical Device Control Division. Full CSDT transfer procedure, updated October 4, 2024.](https://medical.fda.moph.go.th/product/category/transfer-detail-process/) medical.fda.moph.go.th [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-4-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-4-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-4-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-4-4) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-4-5) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-4-6) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-4-7) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-4-8) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-4-9)
5.  [Malaysia MDA, Medical Device Register (MDAR) public device search. Pure Global November 19, 2026 device snapshot analysis described under Methods.](https://mdar.mda.gov.my/frontend/web/?r=carian) mdar.mda.gov.my [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-5-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-5-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-5-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-5-4)
6.  [Malaysia MDA, Licensed Medical Device Establishments public search. Pure Global March 10, 2026 licence snapshot analysis described under Methods.](https://mdar.mda.gov.my/frontend/web/?r=carianfrontend/web?r=carian-el%2Findex) mdar.mda.gov.my [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-6-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-6-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-6-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-6-4)
7.  [Singapore HSA, Listing of Registered Medical Devices, dataset d\_8cfe111e0a5a5cf5b598e78851e58ad4. Pure Global September 3, 2026 analysis described under Methods.](https://data.gov.sg/datasets/d_8cfe111e0a5a5cf5b598e78851e58ad4/view) data.gov.sg [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-7-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-7-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-7-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-7-4)
8.  [Thai FDA public health products search, medical device category. Pure Global June 22, 2026 term-expanded snapshot, selection described in Section 6.](https://porta.fda.moph.go.th/fda_search_center_new/) porta.fda.moph.go.th [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-8-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-8-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-8-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-8-4)
9.  [ASEAN Agreement on Medical Device Directive, including common risk classification and submission template.](https://dev.agreement.asean.org/legal-instrument/asean-agreement-on-medical-device-directive/) dev.agreement.asean.org [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-9-1)
10.  [ASEAN Secretariat. Key documents, including ASEAN Medical Device Directive and Annex 5 on the Post-Marketing Alert System.](https://asean.org/our-communities/economic-community/standards-technical-regulations-and-conformity-assessment-procedures/key-documents-publications/) asean.org [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-10-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-10-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-10-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-10-4)
11.  [Parliament of Malaysia. Medical Device Act 2012 (Act 737).](https://portal.mda.gov.my/index.php/documents/regulation/685-medical-device-act-2012-eng/file) portal.mda.gov.my [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-11-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-11-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-11-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-11-4) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-11-5) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-11-6)
12.  [Republic of Indonesia. Law No. 17 of 2023 on Health.](https://peraturan.bpk.go.id/Details/258028/uu-no-17-tahun2023) peraturan.bpk.go.id [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-12-1)
13.  [Indonesia Ministry of Health. Permenkes No. 62 Tahun 2017, historical distribution licence rule, repealed by No. 5 of 2026.](https://peraturan.bpk.go.id/Details/112243/permenkes-no-62-tahun-2017) peraturan.bpk.go.id [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-13-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-13-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-13-3)
14.  [Republic of Indonesia. Government Regulation No. 28 of 2024 implementing Law No. 17 of 2023 on Health.](https://peraturan.bpk.go.id/Details/294077/pp-no-28-tahun-2024) peraturan.bpk.go.id [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-14-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-14-2)
15.  [Indonesia Ministry of Health. e-Info Alkes and Mobile Alkes product search, by distribution licence number or product name. Pure Global November 19, 2026 product snapshot and analysis.](https://mobilealkes.kemkes.go.id/cari-produk) mobilealkes.kemkes.go.id [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-15-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-15-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-15-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-15-4)
16.  [Indonesia Ministry of Health. e-Info Alkes, Daftar Izin Distribusi Alat Kesehatan (IDAK). Pure Global July 6, 2026 licence snapshot and analysis.](https://infoalkes.kemkes.go.id/idak) infoalkes.kemkes.go.id [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-16-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-16-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-16-3)
17.  [Indonesia Ministry of Health, e-Regalkes technical guidance, section on changes to distribution licences and replacement distributor applications. Confirm current application under the 2026 transition.](https://regalkes.kemkes.go.id/informasi_alkes/Pedoman%20Penilaian%20Alkes%20Permenkes.pdf) regalkes.kemkes.go.id [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-17-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-17-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-17-3)
18.  [Republic of Indonesia. Government Regulation No. 64 of 2019, types and tariffs of non-tax state revenue at the Ministry of Health. Confirm the applicable fee at filing.](https://peraturan.bpk.go.id/Details/120630/pp-no-64-tahun-2019) peraturan.bpk.go.id [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-18-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-18-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-18-3)
19.  [Republic of Singapore. Health Products Act 2007 (2020 Revised Edition), Singapore Statutes Online, Attorney-General's Chambers.](https://sso.agc.gov.sg/Act/HPA2007) sso.agc.gov.sg [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-19-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-19-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-19-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-19-4)
20.  [Singapore Statutes Online. Health Products (Medical Devices) Regulations 2010.](https://sso.agc.gov.sg/SL/HPA2007-S436-2010) sso.agc.gov.sg [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-20-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-20-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-20-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-20-4) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-20-5) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-20-6) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-20-7) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-20-8) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-20-9) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-20-10) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-20-11)
21.  [Singapore HSA, medical device guidance collection, GN-15 R15, its Letter of Authorisation template and GN-24 R2.](https://www.hsa.gov.sg/medical-devices/guidance-documents/) hsa.gov.sg [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-21-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-21-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-21-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-21-4)
22.  [Singapore HSA. Medical device fees and turnaround times, March 26, 2026.](https://www.hsa.gov.sg/medical-devices/fees/) hsa.gov.sg [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-22-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-22-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-22-3) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-22-4) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-22-5)
23.  [Singapore HSA. Notify changes to registered medical devices, GN-21 categorization and implementation steps.](https://www.hsa.gov.sg/medical-devices/registration-of-medical-devices/change-notification/) hsa.gov.sg [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-23-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-23-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-23-3)
24.  [Medical Device Authority Malaysia. Good Distribution Practice for Medical Devices (GDPMD), MDA/RR No. 1.](https://mda.gov.my/documents/guidance-documents/1781-good-distribution-practice-for-medical-devices-gdpmd) mda.gov.my [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-24-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-24-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-24-3)
25.  [Medical Device Authority (MDA), Malaysia. MeDC@St 2.0+ Medical Device Centralized Online Application System, accessed November 2026.](https://medcast.mda.gov.my/) medcast.mda.gov.my [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-25-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-25-2)
26.  [Malaysia MDA. Establishment Licence Information, licence roles and Activity Section 15 requirements.](https://www.mda.gov.my/index.php/industry/establishment-licence/establishment-license-information) mda.gov.my [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-26-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-26-2)
27.  [Malaysia Medical Device (Amendment) Regulations 2025, P.U. (A) 330, Fifth Schedule modifications.](https://portal.mda.gov.my/index.php/documents/ukk/3859-pua-330-2025-2) portal.mda.gov.my [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-27-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-27-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-27-3)
28.  [Medical Device Authority Malaysia. Legislation list, including Medical Device (Duties and Obligations of Establishments) Regulations 2019, P.U. (A) 318.](https://www.mda.gov.my/index.php/ms/senarai-dokumen/perundangan) mda.gov.my [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-28-1)
29.  [Thai FDA, Medical Devices laws collection, entry 1 for the Medical Devices Act and amendment and entries 2–6 for import, product and vigilance instruments.](https://en.fda.moph.go.th/cat2-health-products/category/health-products-medical-devices) en.fda.moph.go.th [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-29-1)
30.  [Thai FDA. New importer guidance, including establishment and route-specific product fee references.](https://medical.fda.moph.go.th/customer-journey/newimporter) medical.fda.moph.go.th [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-30-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-30-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-30-3)
31.  [Thai FDA, Medical Device Control Division. Establishment registration and renewal FAQ.](https://medical.fda.moph.go.th/faqs/category/faq-cate-01/) medical.fda.moph.go.th [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-31-1) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-31-2) [↩](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026#cite-31-3)

[Canonical page](https://www.pureglobal.com/blog-posts/2026-11-23-southeast-asia-medical-device-in-country-representation-handover-workpaper-2026)
